These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22998776)

  • 1. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
    Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
    J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and correlation of sodium/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma.
    Wang ZF; Liu QJ; Liao SQ; Yang R; Ge T; He X; Tian CP; Liu W
    Tumori; 2011; 97(4):540-6. PubMed ID: 21989446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
    Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
    Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    Cheng W; Liu R; Zhu G; Wang H; Xing M
    J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.
    Orim F; Bychkov A; Shimamura M; Nakashima M; Ito M; Matsuse M; Kurashige T; Suzuki K; Saenko V; Nagayama Y; Yamashita S; Mitsutake N
    Thyroid; 2014 Mar; 24(3):502-10. PubMed ID: 23924149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
    Franco AT; Malaguarnera R; Refetoff S; Liao XH; Lundsmith E; Kimura S; Pritchard C; Marais R; Davies TF; Weinstein LS; Chen M; Rosen N; Ghossein R; Knauf JA; Fagin JA
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1615-20. PubMed ID: 21220306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
    Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of sodium/iodide transporters and thyroid stimulating hormone receptors in thyroid cancer patients and its correlation with iodine nutrition status and pathology.
    Li J; Dong JN; Zhao Z; Lv Q; Yun B; Liu JQ; Cai XY
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4573-4580. PubMed ID: 30058701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes.
    Oler G; Nakabashi CD; Biscolla RP; Cerutti JM
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1313-6. PubMed ID: 19169486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
    Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
    D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
    J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
    Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
    Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.
    Hoffmann S; Maschuw K; Hassan I; Wunderlich A; Lingelbach S; Ramaswamy A; Hofbauer LC; Zielke A
    Endocrine; 2006 Aug; 30(1):129-38. PubMed ID: 17185801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
    Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
    Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canine follicular cell and medullary thyroid carcinomas: Immunohistochemical characterization.
    Jankovic J; Tièche E; Dettwiler M; Hahn K; Scheemaeker S; Kessler M; Daminet S; Rottenberg S; Campos M
    Vet Pathol; 2024 Jul; 61(4):524-533. PubMed ID: 38098215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
    Zhang Z; Liu D; Murugan AK; Liu Z; Xing M
    Endocr Relat Cancer; 2014 Apr; 21(2):161-73. PubMed ID: 24243688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.